



Figure S1

A Ccnd3 staining (96 hours post activation)



B Proliferation in presence of IL-2



C Propidium Iodide⁺ cells




Figure S2




Figure S1: A) Staining of WT and *Mll1*^{+/-} CD4 cells with Ccnd3 at 96 hours post activation. Data for the entire timecourse is depicted in 3F B) Proliferation of WT and *Mll1*^{+/-} CD4 cells at 96 hours post activation in the presence and absence of 10 ng/mL IL-2. IL-2 was added from the beginning of the culture. **p*<0.05 as determined by one way ANOVA. C) Assessment of cell death in WT and *Mll1*^{+/-} cultures from 120 hours - 192 hours post activation. **p*<0.01 as determined by one way ANOVA.

Figure S2: A) Staining of WT and *Mll1*^{-/-} cells with anti-*Mll1* antibody. B) Assessment of *Mll1*⁺ expression viable CD4⁺ cells in response to increasing doses of IL-12. **p*≤0.01 as determined by two way ANOVA. C) Incorporation of the nucleotide analog EDU into Th1 cell cultures from WT or *Stat4*^{-/-} mice or WT mice treated with CP690,550 at 72 hours post activation. **p*≤0.05 as determined by one way ANOVA. D) Analysis of STAT4 binding to the PRRIII locus within the promoter of *Il2ra* and to a confirmed STAT6 binding site within the *Rad50* locus in murine T cells. Results are pooled from 3 separate experiments. Cells were taken for analysis at 96 hours post activation. E) Analysis of STAT4 binding to the PRRIII locus and a confirmed STAT6 binding site in human Th0 and Th1 cells and Th1 cells treated with CP690,550. Results are pooled from two donors. Cells were analyzed at 144 hours post activation.